News-Medical.Net

Hypoxia-gated AAV enables targeted treatment for advanced NSCLC

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes ...

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...

Genethon and Ampersand Biomedicines announce partnership to design novel AAV vectors with enhanced tissue specificity for more effective and better tolerated gene therapies

Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship Pioneering multi-product platform company developing smarter ...

CryoTEM breaks ground as new method added to U.S. Pharmacopeia’s updated AAV reference standard certificates

USP recognizes CryoTEM for characterizing empty/full/intermediate capsids on AAV8 reference standards STOCKHOLM, ...
Morningstar

Dyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

New capsids Dyno-9zh and Dyno-n96 for central nervous system (CNS) and muscular gene delivery expand Dyno's portfolio of AI-engineered vectors and create more delivery options for therapeutic ...
Pharmabiz

Genethon, Ampersand Biomedicines partner to design novel AAV vectors with enhanced tissue specificity for effective tolerated gene therapies

Genethon, Ampersand Biomedicines partner to design novel AAV vectors with enhanced tissue specificity for effective tolerated gene therapies: France Saturday, May 23, 2026, 16:00 ...